Biogen (BIIB) Cost of Revenue (2009 - 2026)

Biogen has reported Cost of Revenue for 18 years, with the latest figure at $776.9 million in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 28.41% year-over-year to $776.9 million in Q2 2026; TTM through Jun 2026 was $2.6 billion, a 6.16% increase from a year earlier, with the FY2025 full-year figure at $2.4 billion, up 4.06% from the prior year.
• Cost of Revenue was $776.9 million for Q2 2026 at Biogen, up from $661.0 million in the prior quarter.
• The five-year high for Cost of Revenue was $776.9 million in Q2 2026, with the low at $164.0 million in Q4 2022.
• Average Cost of Revenue over 5 years is $561.3 million, with a median of $598.8 million recorded in 2023.
• The largest YoY upside for Cost of Revenue was 255.79% in 2024 against a maximum downside of 18.2% in 2024.
• Over 5 years, Cost of Revenue stood at $164.0 million in 2022, then changed by 0.0% to $164.0 million in 2023, then jumped by 255.79% to $583.5 million in 2024, then dropped by 15.08% to $495.5 million in 2025, then jumped by 56.79% to $776.9 million in 2026.
• The last three Cost of Revenue figures came in at $776.9 million (Q2 2026), $661.0 million (Q1 2026), and $495.5 million (Q4 2025), per Business Quant data.